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AspirinAbstract Kawasaki disease (KD) is an acute, self-limited vasculitis of unknown etiology that
occurs predominantly in infants and children younger than 5 years of age. Coronary artery abnor-
malities are the most serious complication.
Based on the literatures infusion of Intravenous Immunoglobulin of 2 g/kg and a high dose of
oral aspirin up to 100 mg/kg/day are the standard treatment for Kawasaki disease in the acute
stage, and should be followed by antiplatelet dose of aspirin for thrombocytosis. Glucose-6-Phos-
phate Dehydrogenase (G6PD) deﬁciency is an inherited X-linked hereditary disorder, and aspirin
can induce hemolysis in patients with G6PD deﬁciency. We report a case of a 5 year and 8 month
old male with KD and G6PD deﬁciency.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Kawasaki disease was ﬁrst described in 1967 by Tomisaku
Kawasaki and has replaced acute rheumatic fever as the lead-
ing cause of acquired heart disease among children in devel-
oped countries (Taubert et al., 1991). KD is an acute, self-
limited vasculitis of unknown etiology that occurs predomi-
nantly in infants and young children (Newburger et al.,
2004). The exact etiology of KD remains unknown, althoughgenetic predisposition or infectious agents are likely to be the
cause.
Recently, guidelines were published by the American Heart
Association (AHA) to aid in the diagnosis and management of
Kawasaki disease. Some children classiﬁed as atypical KD
patients because they present with incomplete clinical features
of KD instead of classical criteria. Typical KD diagnosed by
clinical criteria include fever 39–40 C for at least 5 days, how-
ever it could be lasting for 11 days if untreated with concurrent
presence of four of other criteria or at least three if coronary
artery aneurysms developed. Coronary artery aneurysms or
ectasia develop in 15 –25% of untreated children with the dis-
ease and may lead to myocardial infarction (MI), sudden
death, or ischemic heart disease (Newburger et al., 2004).
Other surrogate parameters can be elevated during acute phase
include CRP and ESR however CRP test more accurate in case
of patient recently treated with IVIG because IG can elevate
ESR.
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AHA recommendation guideline with single dose of IVIG
(2 g/kg) and a high dose aspirin (80–100 mg/kg/d, divided into
four doses). Aspirin continued indeﬁnitely in patient with cor-
onary artery abnormalities or until six to eight weeks in nor-
mal ﬁnding. Repeat IVIG in patients who failed to initial
therapy those with persistent or recurrent fever >36 h after
completion of initial IVIG infusion.
The new data shows that it is unnecessary to expose chil-
dren to high- or medium-dose aspirin therapy in acute KD
when the available data show no appreciable beneﬁt in pre-
venting the failure of IVIG therapy or CAL formation or in
shortening fever duration (Weng and Ou, 2011). Long term
management of KD differs according to the risk level of coro-
nary artery abnormalities.
G6PD deﬁciency is an inherited X-linked disorder. It causes
a spectrum of disease including neonatal hyperbilirubinemia,
acute hemolysis, and chronic hemolysis. Different gene muta-
tions cause different levels of enzyme deﬁciency, with classes
assigned to various degrees of deﬁciency and disease manifes-
tation. The levels of enzyme deﬁciency categorized from
severe, moderate, and mild to none (Frank, 2005).
We report a case of KD with G6PD compare it with estab-
lished knowledge available based on guidelines and review
articles.
2. Case report
5 years and 8 months old Saudi boy, 18 kg weight was admit-
ted to the pediatric department. Patient was healthy until
2 weeks prior to admission, when he started to have gastroen-
teritis with fever and received treatment in another hospital for
which diarrhea improved but fever persisted. Two days prior
to admission, he was seen in pediatric clinic and diagnosed
as case of tonsillitis with adenoid hypertrophy and treated with
amoxicillin–clavulanate and planed for surgery, however his
fever persisted and there was swelling of dorsum of both feet
with inability to walk due to pain, so he came back for follow
up and was advised to be admitted for query Kawasaki.
On admission his vital signs were: temperature 39 C, blood
pressure 100/50 mmHg, heart rate 104 beats/minute, oxygen
saturation 98% on room air with no distress. He has enlarged
congested kissing tonsils, bulbar conjunctivitis, cracked lips,
bilateral cervical lymphadenopathy, Bilateral swollen and ten-
der dorsum of the foot, tender calf muscles, swollen and tender
left dorsum of the hand, and skin peeling in the ﬁngers.
Blood investigations on the ﬁrst day of admission were:
WBC 9.22 · 103/lL with 45.5% Neutrophil 39.6% Lympho-
cyte, Hemoglobin 8.4 g/dl, Hematocrit 27.6%, MCV 62.3 ﬂ,
RDW 41.1%, platelet count 486 · 103/lL. Blood ﬁlm showed
microcytic hypochromic anemia with marked anisopoikilocy-
tosis and picture of hereditary Elliptocytosis with reticulocyte
of 7.7%. Blood chemistry showed sodium 132 mmol/l, potas-
sium 4.4 mmol/kg, chloride 101 mmol/l, carbon dioxide
23 mmol/l, ionized calcium 1.16 mmol/l, serum creatinine
43 umol/l, urea nitrogen 2.3 mmol/l, Aspartate aminotransfer-
ase 25 IU/l, Alanine aminotransferase 26 IU/l, C-Reactive
Protein 18.5 mg/l and Erythrocyte Sedimentation Rate
60 mm/h. G6PD was 4 mIU, Rheumatoid factor was negative
<10.0 IU/ml, C3, C4, Antinuclear Antibody and urine analy-
sis were normal too.Echocardiography done at the day of admission and
showed Right Coronary Artery diameter of 3.2 mm at its main
stem and 3 mm at its distal part. Left Coronary Artery diam-
eter was 3.1 at its origin and normal 2.2 mm at its end. No
effusion or chamber dilatation.
Patient with persistent fever with four clinical features of
KD with abnormal coronary artery and elevation of inﬂamma-
tory markers diagnosed as case of Kawasaki disease, G6PD
and microcytic hypochromic anemia. Patient was treated with
single dose of Intravenous Immunoglobulin 2gm/kg over 12 h
with no anti-inﬂammatory dose of aspirin.
On the second day, fever subsided, feet and hands swelling
improved.
Echocardiogram was done on the fourth day of admission
which revealed normalization of the coronary arteries lesions
with normal myocardial function, and Dipyridamole was
started as an anti-platelet at a dose of 4 mg/kg. In the next
day the patient developed bloody diarrhea, Dipyridamole
was stooped as it could be the cause and investigations
were done: stool analysis was done twice over 2 days
and it was normal except for positive occult blood stool, clos-
tridium difﬁcile negative. The third Stool analysis showed
entameba histolytica which was treated successfully with
metronidazole.
Blood indices were: iron 7 lmol/l, total iron binding capac-
ity of 30 lmol/l, ferritin of 123.3 ng/ml, so iron supplementa-
tion was started.
Patient came for follow up after two weeks of discharge.
Echocardiogram showed normal coronary arteries both right
and left with good myocardial function. Electrocardiogram
was normal. Complete Blood Count showed improvement of
anemia as Hb 9.0 g/dl, Hct 27.5%, MCV 55.7 ﬂ, and RDW
35.4%.platelet was 486 · 103/lL, so the patient was started
on a low dose aspirin of 81 mg once daily.
CBC was repeated later and revealed hemoglobin of 10.5 g/
dl and platelet of 406 · 103/lL, so aspirin was stooped. And
echocardiogram was done 6 months after the initial presenta-
tion as a follow-up and was normal.
3. Discussion
According to the AHA guideline, acute management of KD
include single infusion of 2 g/kg IVIG (level of evidence C)
in combination with a high dose aspirin (80–100 mg/kg/day
in 4 divided doses) that appear to possess additive anti-inﬂam-
matory effects (Kuo et al., 2011). High dose aspirin is discon-
tinued after child has been afebrile for 48–72 h then begin low
dose aspirin (3–5 mg/kg/day) for 6–8 weeks if patient showed
no further abnormalities of coronary artery (level of evidence
C) or indeﬁnitely for children developed coronary artery
abnormalities (level of evidence B) (Newburger et al., 2004).
Children are at risk of developing Reye’s Syndrome when tak-
ing aspirin while experiencing active inﬂuenza or Varicella
infection. Children who take aspirin for long term should
receive annual inﬂuenza vaccine. Patients with G6PD deﬁ-
ciency most likely have hemolytic anemia that caused by infec-
tion, ingestion of fava beans, or exposure to an oxidative drug
(Frank, 2005).
However, this patient treated successfully with a single
dose of IVIG alone without aspirin conﬁrming the new
available data that show it is unnecessary to expose children
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data show no appreciable beneﬁt in preventing the failure of
IVIG therapy or Coronary Artery Lesion formation or in
shortening fever duration (Weng and Ou, 2011).
In the Andrew C. Lau, 1 study, she examined the efﬁcacy of
IVIG and salicylate (the active metabolite of aspirin) in inhib-
iting the 3 critical steps in disease pathogenesis of KD: T cell
activation, TNF production, and TNF-mediated MMP-9
expression. Basically the TNF induced MMP-9 activity in
smooth muscle cells is key to the development of coronary
artery disease. In other hand, T cell activation leading to
TNF-mediated MMP-9 activity is therefore a critical pathway
in the development of coronary artery elastin breakdown in
KD. IVIG was capable of inhibiting this mechanism even at
subtherapeutic concentrations. However, Salicylate at thera-
peutic concentration cannot inhibit any of the 3 processes
examined, and IVIG was not able to overcome the undesirable
effects of salicylate-induced TNF expression. This implies that
the usefulness of aspirin may be limited to its antiplatelet and
antipyretic actions, which can be achieved at much lower doses
(Lau, 2009).
As a result treatment of KD with IVIG only without
aspirin in acute-stage had no effect on the response rate of
IVIG therapy, duration of fever, or Coronary Artery Lesion
incidence.4. Conclusion
KD is successfully treated with single dose IVIG without high
or moderate doses of aspirin with good improvement of coro-
nary artery disease and fever that promisingly giving good
treatment option especially for G6PD deﬁciency patient.
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